International Journal of Nephrology characterization in rabbit,” The Journal of Biological Chemistry, vol. 269, no. 31, pp. 19953–19962, 1994. [24] B. L. Wharram, M. Goyal, P. J. Gillespie et al., “Altered podocyte structure in GLEPP1 (Ptpro)-deﬁcient mice asso- ciated with hypertension and low glomerular ﬁltration rate,” Journal of Clinical Investigation, vol. 106, no. 10, pp. 1281– 1290, 2000. [25] L. Barisoni, W. Kriz, P. Mundel, and V. D’Agati, “The dysregu- lated podocyte phenotype: a novel concept in the pathogenesis of collapsing idiopathic focal segmental glomerulosclerosis and HIV-associated nephropathy,” Journal of the American Society of Nephrology, vol. 10, no. 1, pp. 51–61, 1999. [26] E. Kavoura, H. Gakiopoulou, H. Paraskevakou et al., “Immunohistochemical evaluation of podocalyxin expression in glomerulopathies associated with nephrotic syndrome,” Human Pathology, vol. 42, no. 2, pp. 227–235, 2011. [27] H. K. Yap, W. Cheung, B. Murugasu, S. K. Sim, C. C. Seah, and S. C. Jordan, “Th1 and Th2 cytokine mRNA proﬁles in childhood nephrotic syndrome: evidence for increased IL-13 mRNA expression in relapse,” Journal of the American Society of Nephrology, vol. 10, no. 3, pp. 529–537, 1999. [28] L. Le Berre, C. Herve´, F. Buzelen, C. Usal, J. P. Soulillou, and J. Dantal, “Renal macrophage activation and Th2 polar- ization precedes the development of nephrotic syndrome in Buﬀalo/Mna rats,” Kidney International, vol. 68, no. 5, pp. 2079–2090, 2005. [29] K. W. Lai, C. L. Wei, L. K. Tan et al., “Overexpression of interleukin-13 induces minimal-change-like nephropathy in rats,” Journal of the American Society of Nephrology, vol. 18, no. 5, pp. 1476–1485, 2007. [30] R. L. Pereira, V. O. Reis, P. Semedo et al., “Invariant natural killer T cell agonist modulates experimental focal and segmental glomerulosclerosis,” PLoS ONE, vol. 7, no. 3, Article ID e32454, 2012. [31] L. Mesnard, A. D. C. Keller, M. L. Michel et al., “Invariant natural killer T cells and TGF-β attenuate anti-GBM glomeru- lonephritis,” Journal of the American Society of Nephrology, vol. 20, no. 6, pp. 1282–1292, 2009. [32] W. A. Border and E. Ruoslahti, “Transforming growth factor-β1 induces extracellular matrix formation in glomeru- lonephritis,” Cell Diﬀerentiation and Development, vol. 32, no. 3, pp. 425–431, 1990. [33] S. J. Shankland, C. Hugo, S. R. Coats et al., “Changes in cell-cycle protein expression during experimental mesangial proliferative glomerulonephritis,” Kidney International, vol. 50, no. 4, pp. 1230–1239, 1996. [34] S. J. Shankland, “Cell-cycle control and renal disease,” Kidney International, vol. 52, no. 2, pp. 294–308, 1997. [35] M. Schiﬀer, G. Von Gersdorﬀ, M. Bitzer, K. Susztak, and E. P. Bottinger, “Smad proteins and transforming growth factor-β signaling,” Kidney International, Supplement, vol. 58, no. 77, pp. S45–S52, 2000. [36] H. W. Schnaper, T. Hayashida, and A. C. Poncelet, “It’s a Smad world: regulation of TGF-β signaling in the kidney,” Journal of the American Society of Nephrology, vol. 13, no. 4, pp. 1126– 1128, 2002. [37] W. A. Border and N. A. Noble, “Transforming growth factor β in tissue ﬁbrosis,” The New England Journal of Medicine, vol. 331, no. 19, pp. 1286–1292, 1994. [38] M. Schiﬀer, M. Bitzer, I. S. D. Roberts et al., “Apoptosis in podocytes induced by TGF-β and Smad7,” Journal of Clinical Investigation, vol. 108, no. 6, pp. 807–816, 2001. 5 [39] J. Strehlau, A. D. Schachter, M. Pavlakis, A. Singh, A. Tejani, and T. B. Strom, “Activated intrarenal transcription of CTL- eﬀectors and TGF-β1 in children with focal segmental glomerulosclerosis,” Kidney International, vol. 61, no. 1, pp. 90–95, 2002. [40] Y. Li, Y. S. Kang, C. Dai, L. P. Kiss, X. Wen, and Y. Liu, “Epithelial-to-mesenchymal transition is a potential pathway leading to podocyte dysfunction and proteinuria,” American Journal of Pathology, vol. 172, no. 2, pp. 299–308, 2008. [41] Y. Yamaguchi, M. Iwano, D. Suzuki et al., “Epithelial-mes- enchymal transition as a potential explanation for podocyte depletion in diabetic nephropathy,” American Journal of Kidney Diseases, vol. 54, no. 4, pp. 653–664, 2009. [42] K. Reidy and K. Susztak, “Epithelial-mesenchymal transition and podocyte loss in diabetic kidney disease,” American Journal of Kidney Diseases, vol. 54, no. 4, pp. 590–593, 2009. [43] Y. S. Kang, Y. Li, C. Dai, L. P. Kiss, C. Wu, and Y. Liu, “Inhi- bition of integrin-linked kinase blocks podocyte epithelial- mesenchymal transition and ameliorates proteinuria,” Kidney International, vol. 78, no. 4, pp. 363–373, 2010. [44] H. J. Kim, H. H. Lee, H. D. Yoo, J. Hwa Lee, and S. T. Hong, “Development of a solid-phase binding assay and identiﬁ- cation of nonpeptide ligands for the FynB Src homology 2 domain,” Journal of Pharmaceutical and Biomedical Analysis, vol. 27, no. 1-2, pp. 51–56, 2002. [45] J. Patrakka and K. Tryggvason, “Nephrin—a unique structural and signaling protein of the kidney ﬁlter,” Trends in Molecular Medicine, vol. 13, no. 9, pp. 396–403, 2007. [46] J. Lahdenpera¨, P. Kilpela¨inen, X. L. Liu et al., “Clustering- induced tyrosine phosphorylation of nephrin by Src family kinases,” Kidney International, vol. 64, no. 2, pp. 404–413, 2003. [47] H. Li, J. Zhu, L. Aoudjit et al., “Rat nephrin modulates cell morphology via the adaptor protein Nck,” Biochemical and Biophysical Research Communications, vol. 349, no. 1, pp. 310– 316, 2006. [48] I. M. Blasutig, L. A. New, A. Thanabalasuriar et al., “Phos- phorylated YDXV motifs and Nck SH2/SH3 adaptors act cooperatively to induce actin reorganization,” Molecular and Cellular Biology, vol. 28, no. 6, pp. 2035–2046, 2008. [49] N. Jones, L. A. New, M. A. Fortino et al., “Nck proteins maintain the adult glomerular ﬁltration barrier,” Journal of the American Society of Nephrology, vol. 20, no. 7, pp. 1533–1543, 2009. [50] P. M. Andrews, “Investigations of cytoplasmic contractile and cytoskeletal elements in the kidney glomerulus,” Kidney International, vol. 20, no. 5, pp. 549–562, 1981. [51] P. Mundel, H. W. Heid, T. M. Mundel, M. Kr u¨ger, J. Reiser, and W. Kriz, “Synaptopodin: an actin-associated protein in telencephalic dendrites and renal podocytes,” Journal of Cell Biology, vol. 139, no. 1, pp. 193–204, 1997. [52] J. M. Kaplan, S. H. Kim, K. N. North et al., “Mutations in ACTN4, encoding α-actinin-4, cause familial focal segmental glomerulosclerosis,” Nature Genetics, vol. 24, no. 3, pp. 251– 256, 2000. [53] T. Srivastava, R. E. Garola, J. M. Whiting, and U. S. Alon, “Synaptopodin expression in idiopathic nephrotic syndrome of childhood,” Kidney International, vol. 59, no. 1, pp. 118– 125, 2001. [54] L. Barisoni and P. Mundel, “Podocyte biology and the emerg- ing understanding of podocyte diseases,” American Journal of Nephrology, vol. 23, no. 5, pp. 353–360, 2003.